|Slideshows|November 9, 2016

Curcumin: New Use for an Old Spice?

Although recent reviews caution against overenthusiasm, what if a simple, inexpensive, and extremely low-risk anti-inflammatory was at hand?

View the information in PDF format.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Assessing Antipsychotics as Antidepressant Adjuncts

ByKenneth J. Bender, PharmD, MA

July 21st 2026

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

What's Next for Psychedelics in Psychiatry? COMP360 and Beyond

ByGustavo Alva, MD, DFAPA,Jessica Walters

July 16th 2026

Zuranolone in the Room: Closing the Gap in Postpartum Depression Care

ByLeslie Williams, MD

July 16th 2026

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

ByGustavo Alva, MD, DFAPA

July 11th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Curcumin: New Use for an Old Spice?

Related Content

Assessing Antipsychotics as Antidepressant Adjuncts

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

What's Next for Psychedelics in Psychiatry? COMP360 and Beyond

Zuranolone in the Room: Closing the Gap in Postpartum Depression Care

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation

Assessing Antipsychotics as Antidepressant Adjuncts

Future DSM Plans Overlook Core Problem of Validity

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

Crisis Management and Care Planning in Schizophrenia